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Objectives
We aimed to study the incidence rate, predictors and outcomes of HIV care interruption (HCI) in
Belgium.
Methods
We analysed data for adult patients with at least two HIV care records in the Belgian HIV cohort
between 1 January 2007 and 31 December 2016. An HCI episode was defined as 1 year without an
HIV care record. The HCI incidence rate was analysed using Poisson regression, return to HIV care
using a cumulative incidence function with death as a competing risk, and viral load (VL) status
upon return to HIV care using logistic regression.
Results
We included 16 066 patients accounting for 78 625 person-years of follow-up. The incidence rate
of HCI was 5.3/100 person-years [95% confidence interval (CI) 5.1–5.4/100 person-years]. The
incidence of return to HIV care after HCI was estimated at 77.5% (95% CI 75.7–79.2%). Of those
who returned to care, 43.7% had a VL ≤ 200 HIV-1 RNA copies/mL, suggesting care abroad or
suboptimal care (without an HIV-related care record) in Belgium during the HCI, and 56.3%
returned without controlled VL and were therefore considered as having experienced a real gap in
HIV care; they represented 2.3/100 person-years of follow-up. Factors individually associated with
HCI were no antiretroviral therapy (ART) uptake, lower age, injecting drug use, non-Belgian
nationality, male gender, not being a man who has sex with men, a shorter time since HIV
diagnosis, no high blood pressure and CD4 count < 350 cells/µL.
Conclusions
This study highlights the need to investigate return to care and viral status at return, to better
understand HCI. Identified predictors can help health care workers to target patients at higher risk
of HCI for awareness and support.
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Introduction
Since the introduction of antiretroviral therapy (ART) and
the resulting increase in life expectancy among HIV-
infected people [1], HIV infection has evolved to become
a chronic disease requiring decades of engagement in
dedicated care for more and more patients. Sustained
maintenance of the patients in HIV care and on ART is
crucial to ensure the best outcomes in terms of mortality
and morbidity, and to reduce onward transmission [2].
Nevertheless, this is a challenge for a number of patients
[3].
Retention in care is one of the key stages of the con-
tinuum of HIV care [4,5]. In Belgium, this step is amongst
those with the highest attrition [6]. Improving retention
in care would therefore further support our national
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progress towards the Joint United Nations Programme on
HIV/AIDS (UNAIDS) targets [7].
In Belgium, HIV care is well structured and mainly
centralized in 12 multidisciplinary specialized care cen-
tres, the HIV reference centres (HRCs). Patients might also
consult in other hospitals or in primary care. High ART
uptake (> 97% in 2017) and viral load (VL) control
(> 95% of those on ART) are reported for those in regular
care [8]. HIV care is guided by the European AIDS Clini-
cal Society (EACS) guidelines, which recommend a medi-
cal visit with a VL measurement every 3–6 months [9].
Studies on HIV care interruption (HCI) and loss to fol-
low-up in European countries have reported incidence
rates of around 2.5–3.5/100 person-years [10–12]. In a
large multi-country European cohort study, 50% of the
patients had, between 1995 and 2005, a period of >
1 year without a follow-up visit [13]. In one Belgian
HRC, an incidence rate of loss to follow-up of 5.5/100
persons each year was observed between 1999 and 2009
[14]. Comparison between studies is hampered by differ-
ing approaches for selection of the population studied
and the lack of standardized definitions for ‘loss to fol-
low-up’ and ‘HCI’. This is partly a consequence of the
diversity of situations leading to HCI, as illustrated in
Fig. 1. Patients might permanently leave the national HIV
care system as a result of out-migration, or might receive
care abroad before returning to care in Belgium. Alterna-
tively, patients might have ART renewal in Belgium with-
out HIV medical follow-up and hence without VL
records, which would be considered as suboptimal care.
Finally, patients might experience a real gap in HIV care
before return to care. Disentangling the diverse pathways
underlying HCI will inform actions to improve long-term
maintenance in HIV care.
This study aimed to study HCI in Belgium and to better
understand the drivers of the different pathways, particu-
larly for those experiencing a real gap during their HCI
in Belgium.
Methods
Study setting and population
The Belgian HIV cohort study was set up in 2007. It
includes data on all HIV-infected patients in care in Bel-
gium collected from the AIDS reference laboratories
(ARLs) and the HRCs. All VL measurements in the coun-
try are performed and reported by the ARLs. This pro-
vides a national coverage of the patients in HIV care.
HRCs follow > 80% of the HIV-infected patients in care
in the country. Those not attending HRCs are mainly fol-
lowed up in other hospitals and, less frequently, in pri-
mary care. A description of the Belgian HIV cohort was
previously published [15].
The cohort data include a reliable unique patient iden-
tifier based on a combination of the encrypted civil reg-
istry number and a code using gender and date of birth.
Nevertheless, missing or erroneous records may occur.
This is more frequent for patients with HIV follow-up
outside of HRCs. We therefore focused our analysis on
those in care in HRC to ensure the most reliable patient
identifier.
Fig. 1 Diagram of HIV care interruption pathways. ART, antiretroviral therapy.
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In this study, we analysed data for patients aged ≥
18 years, with at least two records of HIV care in HRCs
between 1 January 2007 and 31 December 2016.
Data collection
Routine individual patient data are collected annually from
HRCs and ARLs. Demographic information and VL results
are collected from both HRCs and ARLs. Clinical and addi-
tional laboratory information is collected from HRCs.
Death data were extracted from medical records and
reported by the HRCs. In addition, some HRC and ARL
databases are linked to Belgium’s civil registry, allowing
identification of additional deaths declared among their
patients.
HIV data collection is performed by Sciensano, the Bel-
gian Scientific Institute of Public Health, which is legally
entitled to carry out HIV surveillance in Belgium (Royal
Decree of 8 October 1996). The HIV surveillance was
authorized by an independent administrative authority
protecting privacy and personal data (https://www.au
toriteprotectiondonnees.be/sites/privacycommission/files/
documents/d%C3%A9lib%C3%A9ration_SS_017_2014.pdf
), and approved by the ethical committee of Ghent
University Hospital (RN B670201420495).
Definition of outcomes and variables
The first outcome studied was the incidence rate of HCI. An
HIV care record was defined as a measurement of CD4
count or VL, or a medical visit in an HRC. The study start
date was defined as 1 January 2007 for those previously in
care in HRCs or as the date of first HIV care record for those
entering care later. An episode of HCI was defined as the
occurrence of 1 year without an HIV care record in HRCs if
the patient did not die or have a VL record outside of HRCs
(reported by ARLs) during this period. In the case of an
HCI, data were censored at the date of the last record pre-
ceding the HCI. In the case of a VL reported outside HRCs
during the 1-year period, patients were considered as hav-
ing shifted to care outside HRCs and were censored at the
date of VL measurement reported by the ARL. Patients who
died were censored at the date of death. If none of these
events occurred, data were censored at 31 December 2016.
Care records were analysed up to 31 December 2017 to
ensure that there was the 1-year period of hindsight
required to define an HCI.
The second outcome studied was the cumulative inci-
dence of return to HIV care, analysed among those pre-
senting an HCI. The analysis period began after the first
year of HCI. It was censored at the date of return to HIV
care, the date of death or 31 December 2017, whichever
occurred first. Return to HIV care was defined as a care
record in an HRC or a VL record outside an HRC (re-
ported by an ARL).
The third outcome studied was the VL status upon
return to HIV care. Patients presenting a VL ≤ 200
copies/mL upon return to care were considered as having
accessed ART during their period of HCI, either through
HIV care abroad or through suboptimal care in Belgium
(ART renewal without VL follow-up). Those having a VL
> 200 copies/mL were classified as having experienced a
gap in care.
The following patient characteristics were assessed for
their association with each outcome: gender, age, mode
of HIV acquisition, nationality, time since diagnosis of
HIV infection, CD4 count, ART uptake, HRC of care and
year of care. Urbanization of place of residence was cate-
gorized into three levels of population density based on a
European method applied to the Belgian census data [16–
18]. Income data for municipality of residence was
retrieved from the Belgian statistical office as the average
net taxable income per capita per municipality [19].
Income was divided into three terciles. High systolic
blood pressure was defined as at least one measurement
> 140 mmHg during follow-up; it was used as an indica-
tor of higher risk of comorbidity. Smoking (at least one
record of smoking during follow-up) and obesity [at least
one measurement of body mass index (BMI) > 30 kg/m2
during follow-up] were used to identify those with an
unhealthy lifestyle. Regularity of care was defined as at
least one HIV care record in each semester during the
year preceding censoring.
Statistical analyses
To deal with missing values among risk factors (proportion
of missing values per variable reported in Table 1), multiple
imputation was applied to the data prior to statistical anal-
yses. The SAS MI procedure was used to generate 10 imputed
data sets (SAS Institute, Cary, NC). The imputation process
included all the studied factors and the postal code as an
auxiliary variable. Models for analyses of HCI, return to
HIV care and VL status at return were applied to each
imputed data set and parameter estimates were subse-
quently combined into a single set of results for each
model using the SAS proc mianalyze statement.
The incidence rate of the first HCI and associated fac-
tors were analysed with Poisson regression. Return to
HIV care for those presenting an HCI was assessed using
the cumulative incidence function (CIF) with death as a
competing risk and associated factors were identified
© 2020 The Authors.
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using cause-specific hazard models. VL status upon
return to HIV care and associated factors were analysed
using logistic regression.
The variables age, time since HIV diagnosis, year of
care, ART and CD4 count were considered time-varying
for the HCI analysis and stratified by Lexis expansion.
For the analyses of return to HIV care and VL status upon
return, their values at the time of HCI were used.
All analyses were performed in SAS EG version 7.13.
Results
Population description
Over the 10-year study period, 18 891 patients were fol-
lowed for HIV in Belgium. Of these, 16 066 (85%)
patients in care in the HRCs were included in the analy-
sis, accounting for 78 625 person-years of follow-up.
Most patients were male, and the median age at inclusion
was 39 years. The reported mode of HIV acquisition was
heterosexual in 52% of patients, men who have sex with
men (MSM) in 42%, injecting drug use (IDU) in 3%,
mother-to-child transmission (MTCT) in 1% and other
(contaminated blood products for transfusion or haemo-
philia treatment) in 2%. Half (53%) of the patients were
Belgians, 29% sub-Saharan Africans, 11% non-Belgian
Europeans and 7% of other nationalities. Table 1 presents
characteristics of the patients.
HIV care interruption and return to HIV care
During the study period, 4151 (25.8%) patients inter-
rupted HIV care, 2160 (13.4%) received care outside
HRCs, 417 (2.6%) died and 9338 (58.1%) were retained in
care without experiencing any of those events. The inci-
dence rate of HCI was 5.3/100 person-years [95% confi-
dence interval (CI) 5.1–5.4/100 person-years].
Of those who had interrupted care for at least 1 year,
2364 (57.0%) subsequently returned to HIV care in an HRC,
421 (10.1%) returned to care outside HRCs, eight (0.2%)
died and 1358 (32.5%) remained out of Belgian HIV care
up to 31 December 2017. After the initial 1-year period of
HCI, the cumulative incidence of return to HIV care within
a maximum period of 8 years was estimated at 77.5% (95%
CI 75.7–79.2%), with 51.4% (95% CI 49.8–53.0%) and
72.4% (95% CI 70.8–73.9%) returning within, respectively,
1 and 5 years (Fig. 2). The median time to return to HIV
care was 179 days [interquartile range (IQR) 50–496 years].
A VL measurement was available upon return into HIV
care for 2695 patients (97%). Of these, 1178 (43.7%) had
a controlled VL, suggesting alternative access to medical
care and ART during the HCI period, and 1517 (56.3%)
had uncontrolled VL and were considered to have experi-
enced a gap in HIV care.
By combining the results of the cumulative incidence
model with the assessment of VL status upon return to
care, incidence rates by type of HCI were estimated. The
incidence rate of HCI related to out-migration was 1.2/
100 person-years in care (22.3% 9 5.3/100 person-years).
The incidence rate of HCI with care abroad or with ART
renewal without VL follow-up was 1.8/100 person-years
in care (77.5% 9 43.7% 9 5.3/100 person-years). HCI
with a gap in HIV care had an incidence rate of 2.3/100
person-years in care (77.5% 9 56.3% 9 5.3/100 person-
years) and HCI followed by death had an incidence rate
of 0.01/100 person-years in care (0.2% 9 5.3/100 person-
years).
Table 1 Sociodemographic and selected behavioural and clinical
characteristics of patients in care for HIV, Belgium, 2007–2016
Characteristic
Sex [n = 16 026; number missing: 40 (0.2%)]
Male 10 560 (65.9)
Female 5448 (34.0)
Other 18 (0.1)
Age at baseline (n = 16 066; number missing: 0)
Age (years) [mean (SD)] 40 (11)
















Nadir CD4 count [n = 15 938; number missing: 128 (0.8%)]
< 350 cells/µL 8396 (52.7)
≥ 350 cells/µL 7542 (47.3)
ART status [n = 15 237; number missing: 829 (5.2%)]
Ever on ART 14 117 (92.6)
No ART 1120 (7.4)
Systolic blood pressure [n = 9430; number missing: 6636 (41.3%)]
High 2909 (30.8)
Normal 6521 (69.2)
Smoking [n = 8887; number missing: 7179 (44.7%)]
Yes 3472 (39.1)
No 5415 (60.9)
BMI [n = 7565; number missing: 8501 (52.9%)]
≥ 30 (obese) 1151 (15.2)
< 30 6414 (84.8)
ART, antiretroviral therapy; BMI, body mass index; IDU, injecting drug
use; MSM, men who have sex with men; MTCT, mother to child trans-
mission; SD, standard deviation; SSA, sub-Saharan African.
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Associated factors
After adjustment, a higher incidence rate of HCI was
strongly associated with no ART uptake and moderately
associated with younger age, IDU, non-Belgian national-
ity, more recent HIV diagnosis and low CD4 count
(Table 2). A lower incidence rate of HCI was moderately
associated with female gender, being MSM and high
blood pressure. Smoking, obesity, urbanization level and
income of place of residence were not associated with the
incidence rate of HCI. Those having regular care during
the last year of observation had a higher incidence rate
of HCI than others. The HCI incidence rates were lower in
the period 2007–2011 compared to the following years.
For those presenting an HCI, return to HIV care was
associated, after adjustment, with younger age and female
gender. HIV diagnosis in more recent years, non-Belgian
nationality, being MSM, other mode of HIV acquisition
and low CD4 count at HCI were associated with a lower
likelihood of return to care. For those who returned to
HIV care, factors associated with experiencing a gap dur-
ing HCI in the multivariable analysis were female gender,
younger age, a more recent HIV diagnosis, no ART
uptake at HCI and a low CD4 count at HCI. Europeans
had a lower risk of gap compared to other nationalities.
Immune status and evolution after a gap in HIV care
Among the patients who returned to care after a gap and
with an available CD4 count at the time of return
(n = 1246), 31.4% had a CD4 count < 200 cells/µL,
23.0% a CD4 count of between 200 and 349 cells/µL and
45.6% a CD4 count of ≥ 350 cells/µL. The mean decrease
in CD4 count during the gap in care was 75 cells/µL/year
(95% CI 68.9–81.2 cells/µL/year).
The incidence rate of death amongst all patients who
remained in HIV care was 0.5/100 person-years (95%
CI 0.5–0.6/100 person-years). In comparison, the inci-
dence rate of death in the year following return to care
after a gap was 1.0/100 person-years (95% CI 0.6–1.7/
100 person-years; P = 0.02), and 2.7/100 person-years
(95% CI 1.4–5.0/100 person-years; P < 0.0001) for
those with a CD4 count < 200 cells/µL upon return to
care.
Discussion
Each year, one in 20 HIV-infected patients in care pre-
sents an HCI in Belgium. This study of data representing
a 10-year period allowed the assessment of longstanding
care relationships for 85% of the patients in care in Bel-
gium even if they changed the centre of HIV care, thanks
to multicentric data collection.
Analysis of return to care and health status upon
return is necessary to disentangle the various possible
reasons for the HCI. The estimated incidence rate of a gap
in HIV care was 2.3/100 HIV-infected persons in care in
Belgium per year. This seems in line with studies in other
Western European countries [10,11] although comparison
should be made with caution given the varying
Fig. 2 Cumulative incidence of return to HIV care and death after the initial 1-year period of HIV care interruption (HCI) in Belgium.
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definitions of HCI and approaches to handling out-migra-
tion in these analyses.
Patients with a gap in HIV care who have detectable
VLs may contribute to HIV transmission in the
community. Moreover, those patients were more vulnera-
ble to poor clinical evolution, with a higher mortality
incidence rate in the year following their return to care,
compared with mortality incidence rates of patients
Table 2 Crude and adjusted relative risks (RRs) for HIV care interruption (HCI), for return to HIV care and for experiencing a gap during HCI,
Belgium, 2007–2016
All patients in HIV care Patients in HCI Patients who returned to care
Crude RR for HCI Adjusted RR for HCI Crude HR for return Adjusted* HR for return Crude OR for gap Adjusted* OR for gap
Gender
Male Ref. Ref. Ref. Ref. Ref. Ref.
Female 1.1 (1.1–1.2) 0.8 (0.8–0.9) 1.2 (1.1–1.3) 1.1 (1.0–1.3) 1.2 (1.0–1.4) 1.4 (1.1–1.6)
Age
18–24 years 3.4 (3.0–3.9) 2.1 (1.8–2.5) 1.1 (0.9–1.3) 1.4 (1.1–1.6) 6.1 (4.2–9.1) 3.9 (2.5–6.2)
25–39 years 2.1 (1.9–2.3) 1.6 (1.4–1.7) 1.0 (0.9–1.1) 1.2 (1.1–1.4) 3.2 (2.6–4.0) 2.5 (1.9–3.2)
40–49 years 1.4 (1.3–1.5) 1.2 (1.1–1.3) 1.1 (1.0–1.2) 1.1 (1.0–1.3) 1.8 (1.4–2.3) 1.7 (1.3–2.1)
≥ 50 years Ref. Ref. Ref. Ref. Ref. Ref.
Mode of HIV acquisition
Heterosexual Ref. Ref. Ref. Ref. Ref. Ref.
MSM 0.7 (0.7–0.8) 0.7 (0.6–0.8) 0.8 (0.8–0.9) 0.9 (0.8–1.0) 1.2 (1.0–1.4) 1.1 (0.9–1.5)
IDU 1.9 (1.6–2.2) 1.5 (1.2–1.8) 1.0 (0.8–1.2) 1.1 (0.9–1.3) 0.9 (0.6–1.4) 0.8 (0.5–1.2)
MTCT 1.1 (0.8–1.5) 0.8 (0.6–1.1) 1.5 (1.1–2.0) 1.1 (0.8–1.6) 1.8 (0.9–3.6) 1.6 (0.7–3.7)
Other 0.9 (0.7–1.1) 0.9 (0.7–1.2) 0.7 (0.5–1.0) 0.7 (0.5–1.0) 0.9 (0.5–1.6) 0.9 (0.5–1.8)
Nationality
Belgian Ref. Ref. Ref. Ref. Ref. Ref.
SSA 1.7 (1.6–1.9) 1.4 (1.3–1.6) 0.8 (0.7–0.8) 0.7 (0.7–0.8) 1.1 (0.9–1.3) 1.1 (0.9–1.3)
European 2.1 (1.9–2.3) 1.8 (1.6–2.0) 0.4 (0.4–0.5) 0.5 (0.4–0.6) 0.9 (0.7–1.2) 0.7 (0.5–1.0)
Other 2.0 (1.7–2.2) 1.5 (1.3–1.7) 0.6 (0.5–0.6) 0.7 (0.5–0.8) 1.0 (0.7–1.4) 0.8 (0.6–1.2)
Systolic BP
Normal Ref. Ref. Ref. Ref. Ref. Ref.
High 0.7 (0.7–0.8) 0.8 (0.8–0.9) 1.1 (1.0–1.2) 1.0 (0.9–1.1) 0.7 (0.6–0.9) 0.9 (0.7–1.1)
Obesity
BMI < 30 Ref. Ref. Ref. Ref. Ref. Ref.
BMI ≥ 30 1.2 (1.1–1.3) 1.1 (1.0–1.3) 1.1 (0.9–1.2) 1.0 (0.9–1.1) 1.0 (0.8–1.4) 1.1 (0.8–1.5)
Smoking
No Ref. Ref. Ref. Ref. Ref. Ref.
Yes 1.0 (0.9–1.0) 1.1 (1.0–1.2) 1.0 (0.9–1.1) 1.1 (0.9–1.2) 1.1 (0.9–1.4) 1.1 (0.8–1.4)
Time since HIV diagnosis
< 1 year 3.2 (2.9–3.5) 1.3 (1.1–1.4) 0.5 (0.4–0.5) 0.5 (0.5–0.6) 4.4 (3.3–5.9) 1.4 (0.7–2.0)
1 to 3 years 1.7 (1.6–1.9) 1.0 (0.9–1.1) 0.7 (0.6–0.7) 0.7 (0.7–0.8) 2.8 (2.2–3.6) 1.1 (0.9–1.3)
> 3 to 10 years 1.3 (1.2–1.4) 1.0 (0.9–1.1) 0.8 (0.7–0.9) 0.8 (0.8–0.9) 1.7 (1.4–2.0) 2.2 (1.7–2.9)
> 10 years Ref. Ref. Ref. Ref. Ref. Ref.
CD4 count
≥ 350 cells/µL Ref. Ref. Ref. Ref. Ref. Ref.
< 350 cells/µL 2.4 (2.2–2.6) 2.2 (2.0–2.4) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 2.1 (1.7–2.6) 2.2 (1.7–2.9)
ART
Yes Ref. Ref. Ref. Ref. Ref. Ref.
No 4.6 (4.3–4.9) 4.4 (4.1–4.7) 0.9 (0.9–1.0) 1.1 (1.0–1.2) 7.0 (5.6–8.8) 5.3 (4.1–6.9)
Degree of urbanization
Low 0.9 (0.8–1.0) 0.9 (0.7–1.0) 1.0 (0.8–1.3) 1.1 (0.9–1.3) 1.0 (0.7–1.4) 1.0 (0.7–1.5)
Mid Ref. Ref. Ref. Ref. Ref. Ref.
High 1.2 (1.1–1.3) 1.0 (0.9–1.1) 0.9 (0.8–1.1) 1.0 (0.9–1.1) 1.1 (0.9–1.4) 1.1 (0.9–1.4)
Municipality income
Low 1.2 (1.1–1.3) 1.0 (0.9–1.2) 0.9 (0.8–1.0) 0.9 (0.8–1.1) 1.0 (0.8–1.3) 1.1 (0.8–1.4)
Mid 1.1 (1.0–1.2) 0.9 (0.8–1.0) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.8–1.2) 1.0 (0.8–1.3)
High Ref. Ref. Ref. Ref. Ref. Ref.
Regularity of HIV care
Regular Ref. Ref. Ref. Ref. Ref. Ref.
Not regular 0.9 (0.8–1.1) 0.8 (0.7–0.9) 1.3 (1.1–1.5) 1.2 (1.0–1.4) 1.1 (0.8–1.6) 1.0 (0.7–1.5)
P < 0.05 statistically significant variables shown in boldface.
ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure; HR, hazard ratio; IDU, injecting drug use; MSM, men who have sex with men;
MTCT, mother to child transmission; OR, odds ratio; SD, standard deviation; SSA, sub-Saharan African.
*Relative risks are adjusted for all variables statistically significant in univariate analysis and HIV reference centre (HRC) and year of HIV care (year of
HCI for the analyses of return to care and gap in care).
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maintained in HIV care. Significantly higher mortality
rates were found in those who had CD4 counts < 200
cells/µL upon return to care. Given that patients with low
CD4 counts had twice the rate of HCI and also a higher
risk of a gap during HCI, this finding suggests that espe-
cially prompt and intensive intervention for retention in
care is required in the case of missed appointments
among patients with low CD4 counts.
ART uptake was the strongest predictor of better reten-
tion in HIV care identified by our analysis. In Belgium,
initiation of ART was contingent upon a CD4 count <
500 cells/µL or the presence of clinical symptoms up to 1
December 2016. From then on, initiation of ART for all
HIV-infected patients was implemented. Observed ART
coverage in the HRCs increased from 75% in 2007 to
97% in 2017 [8]. Given the strong association of ART
with retention in care, we might expect the high ART
coverage to reinforce regular care in recent years and in
the future.
Younger patients were more vulnerable to HCI and to a
gap in HIV care, in line with the findings of other studies
[3,20–23], but were less prone to permanent out-migra-
tion. It may be particularly challenging for young people
to cope at once with the stigmatizing dimension of the
disease, its impact on their sexual and emotional wellbe-
ing and the necessary commitment to life-long medical
care [20,24]. Also, increased mobility of young people
related to relationships, jobs and study might impact on
their capacity to remain in HIV care. Other demographic
predictors of HCI identified in this analysis were male
gender and foreign nationality; those who were male or
of foreign nationality were less likely to return to HIV
care in Belgium as a consequence of higher permanent
out-migration during HCI. MSM were less likely to expe-
rience HCI compared to heterosexuals, as reported in the
literature [10,11,25–27].
Injecting drug users had higher incidence rates of HCI.
Assessment of drug use, including “chemsex”, which has
been increasingly reported among people living with HIV
[28], should be performed regularly for patients in HIV
care to enable provision of targeted advice, support and
possibly referral to drug treatment services for collabora-
tive care. Use of other substances such as alcohol was
identified as a predictor of HCI in other studies [3,20,23],
although no data on these exposures were available in
this study.
Difficulties in facing a recent diagnosis of HIV infec-
tion may contribute to the higher incidence rates of HCI
for those recently diagnosed. For those in HCI, a recent
diagnosis was associated with a higher hazard of no
return to care as a consequence of out-migration, and a
higher risk of a gap for those returning to care in
Belgium. The period following diagnosis is crucial, as
poor engagement in HIV care during the first year fol-
lowing diagnosis is associated with higher mortality
[29]. A greater frequency of medical contacts when initi-
ating treatment increases opportunities for providing tar-
geted support for engagement in HIV care to newly
diagnosed patients facing social or administrative barri-
ers. In contrast to our findings, in both a Spanish and
an English study, recently diagnosed patients had fewer
missed medical appointments [25,30], but these studies
did not examine retention in HIV care over a long per-
iod.
Irregular care did not predict subsequent HCI in our
study. Many of the patients with irregular care according
to our definition had in fact very stable HIV disease
requiring less frequent medical visits. Those in regular
care who experienced more HCI might include patients
identified as more vulnerable to HCI for whom clinicians
plan more frequent visits.
Patients with a higher risk of comorbidity were less
prone to HCI, in line with a previous study showing a
dose–response relationship between the number of
comorbidities and optimal retention [21]. We found no
association between HCI and indicators of unhealthy life-
style, nor with urbanization or income levels of place of
residence. A recent Swiss study also found no association
between neighbourhood socio-economic position and loss
to follow-up [31].
Our analysis of determinants of HCI or a gap in HIV
care was restricted to factors available in the cohort data.
Other individual factors such as mental illness and per-
ceived stigma [32,33] or aspects related to health care
services and external environment [23,32] may also play
a key role in retention in HIV care in Belgium. For exam-
ple, a confident relationship with the HIV care provider
and a facilitating health care structure, with features such
as ease of reach by phone, ease of appointment taking,
extended hours of consultation, automatic text messages
or pre-consultation reminder phone calls and a positive
waiting room experience, have frequently been reported
as facilitators [12,33–36].
Guidelines for HIV care recommend a routine assess-
ment at entry into HIV care of new patients [9]. Based on
the factors identified in this study and in others, the
information gathered might be used to identify patients
at increased risk of HCI and provide them with targeted
support. Peers could play a role here, as shown in UK
and US programmes reporting enhanced patient empow-
erment, retention in care and adherence to treatment fol-
lowing peer interventions [27,37].
Guidelines [9] advise an HIV care visit every 3–
6 months. We used a definition of 1 year without an
© 2020 The Authors.
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HIV care record to allow some flexibility for stable
patients spacing their appointments while remaining
properly followed up. Various metrics have been used
to study regularity of HIV care, each with its own
strengths and weaknesses [30,38]. Our definition is rele-
vant for an epidemiological approach to HCI and its
predictors. In clinical practice, with the aim of early
intervention for patients deviating from regular care to
prevent long-term attrition, monitoring of missed
appointments is more suitable and easier to implement
routinely.
In the case of an HCI or missed appointment, prompt
contact with the patient for return to care is facilitated
if all contact information for the patient is available,
for instance through a systematic assessment at initia-
tion of care of the patient’s agreement to be contacted
and the preferred means of contact. This topic could be
added to the initial assessment section of HIV care
guidelines. Tracing of patients might be facilitated if
they have a regular general practitioner (GP); it has also
been shown that those with a regular GP have fewer
missed appointments [27]. The potential use of the Bel-
gian eHealth [39] system – electronic exchange of
health-related data between health care providers – for
supporting retention and return to care should be fur-
ther explored.
This study helped to disentangle the heterogeneity of
situations underlying HCI by looking at the three main
pathways defined for our analysis. Nevertheless, medical
care during HCI was not fully captured. For instance,
patients returning to care with a controlled VL after HCI
were grouped as a single entity although their individual
care use during HCI may have been diverse, including
care abroad, incarceration and various patterns of access
to ART. Also, the group of patients classified as having
experienced a gap in care based on uncontrolled VL upon
return might present heterogeneity in terms of a partial
or complete gap in care throughout the HCI. Further
research using alternative sources of medical data will
help to refine our understanding of individual HIV care
trajectories.
This study has limitations. First, our analysis did not
include patients receiving care exclusively outside HRCs,
who represented 15% of all patients in HIV care in Bel-
gium during the study period. They differed from those
followed in the HRCs, with slightly more people who
inject drugs, fewer MSM, more women and fewer Bel-
gians [6]. As these characteristics are associated with HCI
incidence rate, our results may slightly underestimate the
national levels of HCI. Secondly, the cohort included both
patients who entered care after the study start date and
patients already in care beforehand. In the case of HCI
and return before the study start date, a subsequent epi-
sode of HCI during the study period would have been
misclassified as first HCI for those patients. Whether inci-
dence rates of repeated and first HCI differ was not cap-
tured by the design of our study. Finally, our HIV
surveillance is linked to Belgium’s civil registry to ascer-
tain death status in some but not all HRCs. Nevertheless,
deaths of patients caused by chronic conditions would
probably have been captured in the medical records of
the HRC where the patients were in care. A few sudden
deaths may have remained unrecorded, and possibly led
to a slight underestimation of the number of deaths in
our results. As only a few deaths would have been
missed, complete absence of care or death records for the
whole follow-up period following HCI was interpreted as
out-migration.
In Belgium, the incidence rate of HCI is low, and less
than half of patients experience a real gap in care during
the interruption. A high level of access to HIV care in
Belgium through fully reimbursed ART and multidisci-
plinary HIV care centres contributes to limit HCI and
facilitate return to HIV care. Young patients, heterosexual
men, foreigners, IDUs, those recently diagnosed, those
with low CD4 counts and those with a lower risk of
comorbidities were found to be at higher risk for HCI and
should be targeted for prevention. Such targeting could
be supported by the addition of a section in HIV care
guidelines on the investigation of HCI risk and means of
contact. Despite the decreasing rate of HIV infection in
Belgium in recent years, the HIV-infected population
continues to grow and live longer [8]. To allow these
individuals to experience the full benefit of therapy and a
good health-related quality of life, awareness and support
for long-term maintenance in HIV care will be increas-
ingly necessary.
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